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Aβ42/PSD-95 colocalisationAlzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by cognitive decline,
formation of the extracellular amyloid β (Aβ42) plaques, neuronal and synapse loss, and activated microglia
and astrocytes. Extracellular chaperones, which are known to inhibit amyloid ﬁbril formation and promote
clearance of misfolded aggregates, have recently been shown to reduce efﬁciently the toxicity of HypF-N
misfolded oligomers to immortalised cell lines, by binding and clustering them into large species. However,
the role of extracellular chaperones on Aβ oligomer toxicity remains unclear, with reports often appearing
contradictory. In this study we microinjected into the hippocampus of rat brains Aβ42 oligomers pre-incubated
for 1 h with two extracellular chaperones, namely clusterin and α2-macroglobulin. The chaperones were found
to prevent Aβ42-induced learning and memory impairments, as assessed by the Morris Water Maze test, and
reduce Aβ42-induced glia inﬂammation and neuronal degeneration in rat brains, as probed by ﬂuorescent immu-
nohistochemical analyses. Moreover, the chaperones were able to prevent Aβ42 colocalisation with PSD-95 at
post-synaptic terminals of rat primary neurons, suppressing oligomer cytotoxicity. All such effects were not effec-
tive by adding pre-formed oligomers and chaperones without preincubation. Molecular chaperones have there-
fore the potential to prevent the early symptoms of AD, not just by inhibiting Aβ42 aggregation, as previously
demonstrated, but also by suppressing the toxicity of Aβ42 oligomers after they are formed. These ﬁndings elect
them as novel neuroprotectors against amyloid-induced injury and excellent candidates for the design of thera-
peutic strategies against AD.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is a progressive human neurodegen-
erative disorder characterised by cognitive decline, neuronal and syn-
apse loss, and the formation of two pathological lesions, extracellular
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rights reserved.and intracellular neuroﬁbrillary tangles formed by the hyperphos-
phorylated tau protein [1]. Impairment in synaptic function and plas-
ticity might be the most signiﬁcant early event in the pathogenesis of
AD [2,3], with such events being particularly relevant in the hippo-
campal region [4].
Clinicopathological hallmarks of AD correlate with the presence
of soluble Aβ oligomers as the principal neurotoxic agent [2,5,6]. It
has been demonstrated that synaptic plasticity is rapidly disrupted
by Aβ42 oligomers [7–12]. Moreover, Aβ oligomers have been found
to colocalise with postsynaptic density protein 95 (PSD-95) in hippo-
campal and cortical primary neurons [13–15] and impair cognitive
functions of animal models when microinjected in their brains [5,16].
PSD-95 is a critical scaffolding component of postsynaptic terminals
found in excitatory Central Nervous System (CNS) signaling pathways
[17] and clusters of PSD-95 have been established previously as deﬁni-
tive markers for postsynaptic terminals in mature hippocampal and
cortical cell cultures [18–20]. In addition, the concentration of PSD-95
in the brain of AD patients is signiﬁcantly lower than that of normal
brains [21]. Aβ also plays a central role in the pathogenesis of AD as a
mediator of oxidative stress and neuronal cell apoptosis [22–29].
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AD; vulnerable brain regions exhibit activated microglial cells and
astrocytes, which often associate with amyloid deposits suggesting
a central role of these non-neuronal cells in AD pathology [30–33].
It has also been suggested that atrophy of astroglia, which occurs at
the early stages of AD and is likely to accompany early stages of other
neurodegenerative diseases, determines synaptic malfunction, synaptic
loss, and cognitive deﬁcits [34].
Molecular chaperones are proteins that play a central role in the
avoidance of protein misfolding and aggregation [35,36]. Chaperones
are known to have a range of different functions, such as assisting
protein folding [35], inhibiting protein aggregation [37], causing the
disaggregation of aberrant protein oligomers [38], and facilitating the
degradation ofmisfolded proteins [39]. In particular, extracellular chap-
erones, such as clusterin (Clu), haptoglobin (Hp) andα2-macroglobulin
(α2M), have been shown to colocalise with amyloid plaques in AD
[40–42], inhibit Aβ ﬁbril formation in vitro [43–47] and promote the
clearance of protein aggregates via endocytosis [48–50]. It is unclear,
however, whether extracellular chaperones inhibit directly the toxicity
of Aβ oligomers, as reports have often been contradictory, with a few
of them supporting a toxicity-enhancing role [7,51,52], others claiming
a protective action [43,53,54] and one report describing a dose-
dependent effect [46].
Our recent data showed that a representative set of chaperones
can inhibit efﬁciently the toxicity of extracellularly added protein
oligomers formed by three different peptides and proteins in SH-SY5Y
neuroblastoma cells, provided the chaperones are incubated with the
preformed oligomers before the resultingmixtures are added to the ex-
tracellular medium of the cells [54]. Such an inhibition is very effective
as it occurs even at low chaperone concentration [54]. Using preformed
HypF-N oligomers as a representative toxic species, the protective effect
of the chaperones was shown to result from the ability of these proteins
to bind to the oligomers and promote their further assembly into larger
species, in the absence of any signiﬁcant reorganisation of their internal
molecular structure [54].
Following this encouraging result obtained with HypF-N oligo-
mers and cultured neuronal cells, the purpose of this study was to de-
termine whether pre-incubation of Aβ42 oligomers with two types of
extracellular chaperones can prevent Aβ42-induced hippocampal in-
jury in rats following hippocampal microinjection and to determine
how it correlates with reduced brain pathology and behavioural inju-
ries. In these experiments, toxic oligomers from Aβ42 were formed,
incubated with Clu or α2M, and then injected into rat brains or added
to the extracellularmediumof rat primary neurons. Thus, the oligomers
were formed before adding the chaperones, with the aim of assessing
whether the protective action of the latter also includes neutralisation
of toxic oligomers after they have formed. We demonstrate that the
chaperones ameliorate the Aβ42-mediated learning and memory im-
pairment in injected rats, reduce Aβ42-induced glia inﬂammation and
neuronal degeneration in injected rat brains and protect against the
oxidative-stress conditions and apoptotic cell death associated with
Aβ42 exposure. In addition, the extracellular chaperones were found
to prevent Aβ42 binding to PSD-95 in dendritic spines, neutralising olig-
omer toxicity in cultured rat primary neurons.
2. Materials and methods
2.1. Formation of Aβ42 oligomers
Aβ42 were obtained from Sigma-Aldrich (St. Louis, MO). Human
Clu and α2M were puriﬁed as previously reported [55,56]. Aβ42 olig-
omers were prepared as previously described [57] and resuspended
in F12-medium to 12 μM. Native proteins were diluted to 12 μM into
the same medium. Oligomers were incubated in the medium for 1 h
at 37 °C while shaking, without or with chaperones, and then injected
into rats or added to cultured cells. The oligomer:chaperone molarratio was 10:1 for Clu and 100:1 for α2M (Aβ42 is considered as mono-
mers, Clu as αβ dimers and α2M as a tetramer, according to the func-
tional oligomeric state).
2.2. Rat model and cell cultures
Thirty-six three-month-old (220–250 g) male Wistar rats (Harlan
Nossan, Correzzana, Italy) were housed in macrolon cages until sur-
gery andmaintained on a 12-hour light/dark cycle at 23 °C. All animal
manipulations were performed in vivo, according to the European
Community guidelines for animal care (DL 116/92).
Primary cortical and hippocampal neurons were obtained from
embryonic day (ED)-17 Sprague-Dawley rats (Harlan) as described
in Bongers et al. [58]. The experimental procedures were in accor-
dance with the standards set forth in the Guide for the Care and Use
of Laboratory Animals (published by the National Academy of Science,
National Academy Press, Washington, D.C.). The uteri were removed
from the gravid rat under anaesthesia. Cerebral cortices and hippo-
campi were dissociated in sterile Dulbecco's phosphate-buffered saline
(D-PBS; Sigma), and neurons isolated in the same medium containing
trypsin (0.5% in D-PBS) for 10 min at 37 ° C. After centrifugation at
2000 rcf for 5 min, dissociated neuronswere re-suspended in neurobasal
medium (NBM; Gibco, Invitrogen Corporation, Milan, Italy) supple-
mented with 2% (v/v) B-27 (Gibco) and 0.5 mmol/L glutamine (Gibco),
and then plated in poly-L-lysine-coated 96 or 24-well plates at densities
of approximately 1.0 × 104/well and 2.0 × 104/well, respectively.
Cultures were maintained in NBM at 37 ° C in a 5% CO2-humidiﬁed
atmosphere. Neurons were exposed to 12 μM toxic oligomers 14 days
after plating.
2.3. Morris water maze test (MWM)
For in vivo studies, Aβ42 oligomers and chaperoneswere suspended in
F12-medium with 0.1% DMSO at ﬁnal concentrations of 0.45 mg/ml
(100 μM) and 0.7 mg/ml (10 μMfor Clu and 1 μMforα2M), respectively,
and incubated for 1 h at 37 °C while shaking. 1.5 μl aliquots of F12-
medium, F12-medium with Aβ42 oligomers, F12-medium with Aβ42
oligomers and Clu and F12-medium with Aβ42 oligomer and α2M, all
containing 0.1% DMSO, were injected into the Cornu Ammonis (CA) 1
molecular layer of the right hippocampus of anaesthetised (Zoletyl,
45 mg/kg plus Carprofen, 5 mg/kg) rats for each condition, using a
Hamilton microsyringe, at the following stereotaxic coordinates
(in mm): AP,-3.7; L,-2.5 from bregma; and H, 3.5 below the dura
[59]. The injections lasted 3 min, and the microsyringe was left in
the place for 5 min after completing the infusion. Ratswere behaviourally
tested in the MWM 1 week after the intrahippocampal injection of the
different oligomers (n = 6/group). This was considered a reasonable
time period to allow us to detect long-term effects of the injected aggre-
gates in light of their likely persistence in tissue.
The water maze apparatus consisted of a circular pool (160 cm
diameter and 45 cm high) made of plastic. The pool was ﬁlled to a
depth of 30 cm with water (22 ± 1 °C) that was made dark by the
addition of non-toxic dark paint, and virtually divided into four
equivalent quadrants. Rats were tested in the reference memory ver-
sion of MWM with the procedure previously described [60]; brieﬂy,
all rats underwent a reference memory training with a hidden plat-
form (13 cm diameter, submerged 0.5 cm under the water level),
placed in the centre of one quadrant of the pool (northwest) for
4 days, with 4 trials per day, with the four starting locations varied
between trials. Upon release into the water, the rat was allowed to
search the platform for 60 s; if the platform was not located within
the maximum time of 60 s, the rat was guided to the location. The
rat was allowed 20 s on the platform. Extra-maze visual cues around
the room remained in ﬁxed positions throughout the experiment. For
each trial, latency to ﬁnd the platform (maximum 60 s) was recorded
by a video-tracking/computer-digitising system (HVS Image, Hampton,
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the pool and each rat received one 30 s swim “probe trial”. The starting
point was set in the south-east quadrant. Percentage of time spent in
each quadrant and the number of crossing over the platform section
were recorded.
2.4. Fluorescence immunohistochemical analyses of glial activation and
Neu-N
After behavioural evaluations, all rats were deeply anaesthetised
with chloral hydrate (400 mg/kg, i.p.) and killed by decapitation.
Four brains for each conditions were quickly extracted and ﬁxed in
phosphate-buffered 4% paraformaldehyde (pH 7.4) for 24 h at 4 °C,
subsequently rinsedwith PBS, dehydrated using an automatedmachine
and embedded in parafﬁn. Coronal sections (5.0 μm) were cut using
a microtome and mounted on slides. Sections were then incubated in
xylene for 20 min at room temperature, to allow removal of parafﬁn,
and subsequently rehydrated.
Fluorescent labeling followed previously described protocols [61].
Brieﬂy, 5 μm parafﬁn-embedded coronal sections (3 sections of each
brain for each condition) were rinsed 3 times and placed in blocking
solution (PBS, pH 7.4 + 0.3% (v/v) Triton X-100, 2 g/l bovin serum
albumin (BSA) and 5% (v/v) normal goat serum (NGS)) for 30 min
at room temperature (RT). Analysis of glial ﬁbrillary acidic protein
(GFAP)-immunoreactive astrocytes and ionised calcium binding adap-
tor molecule 1 (Iba-1)-labeled microglial cells were carried out over-
night at 4 °C using 1:500 diluted rabbit polyclonal anti-GFAP (Dako,
Glostrup, Denmark) or 1:300 diluted rabbit polyclonal anti-Iba 1
(Wako, Fuggerstrasse, Germany) antibodies diluted in fresh blocking
solution. Sections were then washed in PBS (3× 10 min) at RT and
subsequently incubated for 2 h with Alexa Fluor 488-conjugated
anti-rabbit or Alexa Fluor 594-conjugated anti-rabbit polyclonal anti-
bodies (Invitrogen, Eugene, OR), diluted 1:400 in blocking solution.
Following further rinses, sections were cover-slipped using Vectashield
water-based mounting medium containing DAPI (Vector Laboratories,
Burlingame, CA).
Analysis of neuronal nuclei (Neu-N) were carried out overnight at
4 °C using 1:100 diluted mouse polyclonal anti-Neu-N (Chemicon,
Millipore, Italy) antibodies diluted in fresh blocking solution. Sections
were then washed in PBS (3× 10 min) at room temperature and
subsequently incubated for 2 h with Alexa Fluor 594-conjugated
anti-mouse polyclonal antibodies (Invitrogen) diluted 1:400. Follow-
ing further rinses, sections were cover-slipped using Vectashield
water-based mountingmedium containing DAPI (Vector Laboratories).
In each study the analysis of negative controls (omission of primary an-
tibody)was simultaneously performed in order to exclude the presence
of non-speciﬁc immunoﬂuorescent staining, cross-immunostaining, or
ﬂuorescence bleed-through. Neu-N-positive cells in the hippocampus
were counted under a 10× objective lens of an Olympus Optical
(Tokyo, Japan) BX63 microscope equipped with an Olympus Optical
DP50 digital camera and a cellSens Dimension software. The total num-
ber of counted Neu-N-positive cells, carried out on 3 sections of each
brain for each condition, was averaged, expressed as percentage of
that in the F-12-injected rats, assumed as 100% and analyzed using
Prism 3.0 (GraphPad Software, San Diego, CA).
2.5. Lipid peroxidation analysis and caspase-3 activity assay in
rat hippocampus
The analyses of lipid peroxidation and caspase-3 levels were per-
formed on rat hippocampal homogenates. We microinjected 1.5 μl
aliquots of F12-medium, Aβ42 oligomers and Aβ42 oligomer pre-
incubated with Clu or α2M for 0 h and 1 h, into the right hippocam-
pus of anaesthetised rats. Three hippocampi for each condition were
quickly extracted from rat brains and immediately stored at -80 °C.
Each hippocampus was transferred to ice-cold microcentrifuge tubeswith 200 μl of lysis buffer (50 mM Tris–HCl, pH 7.5, 50 mM NaCl,
10 mM EGTA, 5 mM EDTA, 2 mM sodium pyrophosphate, 4 mM
para-nitrophenylphosphate, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl ﬂuoride (PMSF), plus 20 μg/ml leupeptin and
30 μg/ml aprotinin), and tissues were homogenised on ice (with a
Potter-Elvehjem homogeniser) directly into the Eppendorf tube (20
strokes, 1 stroke/s). Immediately after homogenisation, protein deter-
mination was performed using the method of Bradford [62]. To assess
the rate of lipid peroxidation, the 8-OH isoprostane levels were
measured in rat hippocampal homogenates (5 μg of proteins per well)
using the 8-isoprostane EIA kit (Cayman Chemical Company, Ann
Arbor, MI) at 405 nm, as previously described [63].
The caspase-3 activity assay homogenates were prepared using a
different buffer composition (20 mM Tris-HCl buffer, pH 7.4, con-
taining 250 mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 5 μg/ml
aprotinin, 5 μg/ml leupeptin, 0.5 mM phenylmethylsulfonyl ﬂuoride,
4 mM sodium vanadate, and 1 mM dithiothreitol (DTT)) [64]. To
evaluate the caspase-3 activation, 50 μg of total proteins were diluted
in 50 mM HEPES-KOH buffer, pH 7.0, containing 10% glycerol, 0.1%
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, 2 mM
EDTA, 10 mM DTT and incubated for 4 h at 37 °C in presence of 30 μM
Ac-DEVD-AFC (excitation, 400 nm; emission, 505 nm) (Biomol Research
Laboratories Inc., Plymouth Meeting, PA, http://www.biomol.com).
2.6. MTT reduction assay in cultured neurons
To assess the effects of chaperones on the Aβ42 oligomer cytotoxicity,
we evaluated themitochondrial status using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, on primary rat
hippocampal and cortical neurons seeded in 96-well plates for 24 h
at 37 °C. The MTT reduction assay was performed as described [65].
Preformed oligomers of Aβ42 (12 μMmonomer concentration)were in-
cubated in cell culture medium for different time lengths (0, 5, 15, 30
and 60 min) in the absence or presence of Clu orα2M (Aβ42:chaperone
molar ratio was 10:1 and 100:1 for Clu andα2M, respectively) and then
added to rat neurons for 24 h.
2.7. Measurement of intracellular ROS in cultured neurons
Preformed oligomers of Aβ42 (12 μM monomer concentration)
were incubated for 0 h and 1 h in the cell culture medium with or
without Clu or α2M (oligomer:chaperone molar ratios as described
above) and then added to rat neurons seeded on glass coverslips for
60 min at 37 °C. To detect intracellular ROS production, neurons
were then loadedwith 10 μM2′,7′-dichlorodihydroﬂuorescein diacetate
(CM-H2DCFDA, Molecular Probes), as described previously [66]. Cell
ﬂuorescence was analyzed by the confocal scanning microscope de-
scribed above using the 488 nm excitation line.
2.8. Colocalisation of Aβ42 aggregates with PSD-95 in cultured neurons
Preformed oligomers of Aβ42 (12 μM monomer concentration)
were incubated for 1 h in the cell culture medium with or without
Clu or α2M (Aβ42:chaperone molar ratio as described above) and
then added to rat neurons seeded on glass coverslips for 1 h or 24 h
at 37 °C. Immunolabeling of cultured primary neurons was performed
as previously described [14]. The colocalisation of Aβ42 aggregates
with PSD-95 was monitored using 1:200 mouse monoclonal 6E10
antibody and 1:500 rabbit polyclonal anti-psd-95 antibody (Pierce
Biotechnology, USA) for 60 min at 37 °C, and then with Alexa Fluor
488- and 594-conjugated antibody (Sigma-Aldrich, St. Louis, MO) for
2 h at room temperature. Cell ﬂuorescence was analyzed by confocal
Leica TCS SP5 scanning microscope (Mannheim, Germany) equipped
with laser sources for ﬂuorescence measurements at 488 and 594 nm
and a Leica PlanApo 63× oil immersion objective. A series of optical sec-
tions (1024 × 1024 pixels), 1.0 μm in thickness, were taken through
Fig. 1. Effect of hippocampal injection of Aβ42 oligomers pre-incubated with two extra-
cellular chaperones (Clu and α2M) on MWM performance of rats. Rats were injected
with 1.5 μl of 0.45 mg/ml Aβ42 oligomers in the absence or presence of 0.7 mg/ml
chaperones (protein:Clu molar ratio was 10:1; protein:α2M molar ratio was 100:1).
Control rats were injected with 1.5 μl of medium. (A) Time lengths employed to ﬁnd the
platform during the training session (escape latencies) are reported as mean ± SEM.
Each point represents the mean daily value of four trials of each experimental group
(n = 6 per group). (B) Percentage of time in the target and opposite quadrants (top
panels), percentage of time in the platform section and number of crossings over the
platform position (bottom panels) measured for 30 s on day 4. Data are expressed as
mean ± SEM. (n = 6 per group). The asterisks and the double asterisks indicate signiﬁ-
cant differences (p ≤ 0.05 and p ≤ 0.01, respectively) versus Aβ42-injected rats.
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stant for each analysis. The colocalisation of oligomers with PSD-95
was estimated on regions of interest (12–13 cells) using the ImageJ
(NIH, Bethesda, MD, USA) and JACOP plugin (rsb.info.nih.gov) soft-
wares [67].
2.9. Statistical analysis
MWM data are expressed as mean ± standard error of the mean
(SEM). MTT test, 8-OH isoprostane test and caspase-3 assay were
expressed as mean ± standard deviation (SD). Comparisons between
different groupswere performed using ANOVA followed by Bonferroni's
post-comparison test. A p-value less than 0.05 was accepted as statisti-
cally signiﬁcant.
3. Results
3.1. Chaperones prevented learning and memory impairment in
intra-hippocampus Aβ42-injected rats
Aβ42 oligomers were incubated for 1 h in F-12 medium in the ab-
sence or presence of two types of extracellular chaperones, namely
clusterin (Clu) and α2-macroglobulin (α2M). 1.5 μl aliquots (0.7 μg
Aβ42 with. 1 μg Clu or α2M) were microinjected into the right hippo-
campus of rat brains. Seven days after unilateral injection into the
hippocampus, rats were trained for four days in the Morris water
maze (MWM) to learn where the hidden platform was located. The
ability of rats to acquire, process, and recall spatial information was
assessed by evaluation of the time required to ﬁnd the platform
(escape latency), time in quadrant where the platform is located
(target quadrant), time in the opposite quadrant, time in the small
area where the platform is located (platform section) and number
of crossings over the platform section. The animals were naive to
the water maze and showed no deﬁciencies in swimming abilities, di-
rectional swimming toward the platform, or climbing onto a hidden
platform during training trials. Rats injected only with F12-medium
shortened the escape latency during the 4-days training phase
(Fig. 1A). They were good swimmers and responded to being placed
in water with an appropriate swim-search response. Conversely, Aβ42
oligomer-injected rats showed only a slow decrease in escape latency
during the 4 days of training (Fig. 1A). When we pre-incubated Aβ42
oligomers with Clu or α2M for 1 h and then injected these solutions
intra hippocampus, we obtained a signiﬁcant decrease (p b 0.05) in es-
cape latency, compared with the Aβ42 oligomer-administered group,
particularly at day 3 and 4 (Fig. 1A). Five h after the last test on day 4
it was found that rats treated with Aβ42 oligomers pre-incubated with
Clu or α2M for 1 h spent a signiﬁcantly higher percentage of time in
the target quadrant (p b 0.05), with respect the animals treated with
only Aβ42 oligomers (Fig. 1B, top left). We also observed a marked
reduction of the percentage of time spent in the opposite quadrant
(p b 0.05) in rats treated with Aβ42 oligomers plus Clu or α2M, com-
pared to Aβ42 oligomer-injected rats (Fig. 1B top right). The percentage
of time spent in the adjacent quadrants and the swim speed in target
quadrant during this session was comparable among the groups (data
not shown), indicating that the motility of rats injected with the dif-
ferent samples was not impaired. The analysis of the percentage of
time in the platform section showed a signiﬁcant increase in rats treated
with Aβ42 oligomers plus chaperones, with respect to the Aβ42
oligomer-treated group (Fig. 1B, bottom left). Finally, the number of
crossings over the platform position revealed a signiﬁcant increase in
rats injected with Aβ42 oligomers plus chaperones, compared to the
Aβ42 oligomer-administered group (Fig. 1B, bottom right). Taken to-
gether, these data demonstrated that both types of extracellular chaper-
ones have the ability to prevent the learning and memory impairment
mediated by the intra hippocampus injection of Aβ42 oligomers.3.2. Chaperones reduced glial reaction in Aβ42-exposed rat hippocampus
We then investigated whether chaperones could neutralise Aβ42-
mediated glial inﬂammation, by evaluating glial ﬁbrillary acidic pro-
tein (GFAP)-immunoreactive astrocytes and Iba 1-labelled microglial
cells. Immunoﬂuorescence analyses revealed diminished glial reac-
tion in rats treated with Aβ42 oligomers and chaperones compared
to rats treated with Aβ42 oligomers only (Fig. 2). Such a decrease
was evident by monitoring both GFAP-immunoreactive astrocytes
(Fig. 2A) and Iba 1-labelled microglial cells (Fig. 2B). Hypertrophic
astrocytes with long, thick branches were detected by GFAP immuno-
staining in Aβ42-injected rats (Fig. 2A). In contrast, in rats treated
with Aβ42 and chaperones, astrocyte activation occurred to a much
lesser extent (Fig. 2A). Labeling with anti-Iba-1 antibodies revealed
microglia with small cell bodies and thin, elongated processes in
rats treated with Aβ42 plus Clu or α2M, compared to Aβ42-injected
rats, where microglia with enlarged cell bodies and short, thickened
processes were found (Fig. 2B). This data therefore suggests that
these two extracellular chaperones can protect against the Aβ42
oligomer-mediated glial inﬂammation.
Fig. 2. Analyses of glial activation in the hippocampus of 3-month-old male Wistar rats treated with Aβ42 oligomers pre-incubated with extracellular chaperones. Representative
photomicrographs (10× and 40×magniﬁcations) of ﬂuorescence immunohistochemical analyses of GFAP immunoreactivity (A) and Iba-1-labeled microglial cells (B) obtained 14 d
after injection of 1.5 μl medium, or 1.5 μl of 0.45 mg/ml Aβ42 oligomers in the absence or presence of 0.7 mg/ml chaperones (protein:chaperone molar ratios as described in the
Materials and methods section). GFAP immunoreactivity and Iba-1-labeling are indicated by red and green colours, respectively.
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hippocampus
In AD, the aggregated species of Aβ peptides interact with the
plasma membrane of the affected cells, triggering a free radical-
mediated injury that ultimately results in cell degeneration [68].
The survival of neurons after treatment with Aβ42 oligomers plus
Clu or α2M was examined by using the Neu-N marker. The group
injected with Aβ42 oligomers showed a decreased number of mature
neurons compared to the medium-administered group (Fig. 3A). Con-
versely, rats treated with Aβ42 oligomers preincubated for 1 h with
Clu or α2M showed a high improvement in neuron survival, suggesting
that chaperones can prevent Aβ42-mediated neurodegeneration.
We next evaluated the protective role of the two extracellular
chaperones against Aβ42-induced lipid peroxidation, determined by
measuring 8-OH isoprostane levels. The results showed that 8-OH
isoprostane levels were signiﬁcantly higher in the hippocampal
homogenates of rats treated with Aβ42 oligomers, compared to the
medium-injected groups (Fig. 3B), suggesting an oxidative-stressed
condition associated with Aβ42 oligomer exposure. 8-OH isoprostane
levels were also high after injection of Aβ42 oligomers with Clu or
α2M in the absence of pre-incubation (Fig. 3B). In contrast, the hippo-
campi of rats treated with Aβ42 oligomers and either chaperone in the
presence of preincubation for 1 h before injection showed no difference
in the lipid peroxidation levels with respect to medium-injected rats
(Fig. 3B).
We then analyzed whether the two chaperones can prevent the
Aβ42-induced cell death, by measuring the activity of caspase-3, a
well-recognised apoptotic marker, in rat hippocampal homogenates
[64]. Caspase-3 activation was signiﬁcantly increased in the hippo-
campal homogenates of rats injected with Aβ42 oligomers, with respect
to the rats injected only with F12-medium (Fig. 3C), indicating apopto-
tic cell death associated with Aβ42 oligomer treatment. Caspase-3
activation was also increased in the hippocampal homogenates of rats
injected with Aβ42 oligomers plus Clu or α2M in the absence of
pre-incubation (Fig. 3C). On the other hand, the level of caspase-3 acti-
vation in hippocampi of rats treatedwith Aβ42 oligomers pre-incubatedwith chaperones for 1 h was not signiﬁcantly different to that of rats
injected only with F12-medium (Fig. 3C).
These results suggest that the pre-incubation of Aβ42 oligomers
with chaperones prevents the oxidative-stress conditions associated
with Aβ42 oligomer exposure, avoiding the induction of apoptosis
by the oligomers.
3.4. Chaperones suppressed Aβ42 oligomer-induced cytotoxicity in rat
hippocampal and cortical neurons
To assess the protective role of the two extracellular chaperones
against Aβ42 oligomers, we also used cultures of hippocampal and
cortical neurons extracted from embryonic day (ED)-17 rats and ana-
lyzed in their mature form at day 21. In a ﬁrst set of experiments we
incubated preformed oligomers of Aβ42 in the cell culture medium in
the absence or presence of Clu or α2M for different time lengths, and
then added the resulting mixture to the extracellular medium of cul-
tured primary hippocampal neurons. Aβ42 oligomers showed their
toxic action (Fig. 4A), whereas the neurons treated with oligomers
pre-incubated with Clu or α2M were found to reduce MTT to levels
similar to medium-administered cells (Fig. 4A) and to cells treated
with native Aβ42 (data not shown), with an effect dependent on the
time of preincubation of the oligomers with the chaperones. Similar
data was obtained by pre-incubating Aβ42 oligomers plus chaperones
for 1 h in cultured primary cortical neurons (Fig. 4B). Comparable
results were achieved with preformed oligomers of the N-terminal
domain of the HypF protein from Escherichia coli (HypF-N) (Suppl.
Fig. 1A and B). HypF-N is a valuable model system for investigating
the structural basis of the cellular dysfunction caused by misfolded
protein oligomers, because this protein have the same morphological
and tinctorial features as those formed by disease-related peptides
and proteins [65].
Then we compared the ability of the two extracellular chaperones
to suppress the intracellular ROS production and Ca2+ dyshomeostasis
induced by Aβ42 oligomers. Aβ42 oligomers induced a sharp increase in
ROS (Fig. 4C, D) and cytosolic free Ca2+ (Suppl. Fig. 2) in rat neurons,
which was inhibited by Clu and α2M (Fig. 4C and D and Suppl. Fig. 2).
Fig. 3. Analyses of neuronal degeneration, lipid peroxidation and apoptosis in the hippocampus of 3-month-old male Wistar rats treated with Aβ42 oligomers pre-incubated with
extracellular chaperones. (A) Representative photomicrographs (40×magniﬁcations) of ﬂuorescence immunohistochemical analysis of Neu-N obtained 14 d after injection of 1.5 μl
medium, or 1.5 μl of 0.45 mg/ml Aβ42 oligomers in the absence or presence of 0.7 mg/ml chaperones (protein:chaperone molar ratio as described in the Materials and methods
section). The quantiﬁcation of Neu-N immunoreactivity in the hippocampus after the injections is shown below the images. (B) 8-OH isoprostane levels, a correlate of lipid perox-
idation, in rat hippocampal homogenates (5 μg of proteins per well) at the indicated time lengths of pre-incubation between Aβ42 oligomers and chaperones. (C) Caspase-3 levels
assessed by a ﬂuorimetric assay using the Ac-DEVD-AFC probe, at the indicated time lengths of pre-incubation between Aβ42 oligomers and chaperones. The reported values
(means ± SD) are representative of three independent experiments carried out in triplicate for each experimental group (n = 6 per group). The double and the triple asterisks
indicate signiﬁcant differences (p ≤ 0.01 and p ≤ 0.001, respectively) versus Aβ42-injected rats.
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chaperones were added to the rat neurons in the absence of pre-
incubation (Fig. 4C and Suppl. Fig. 2A), suggesting the importance
of the pre-incubation time. Comparable results were obtained with
HypF-N oligomers (Suppl. Fig. 1C and D and Suppl. Fig. 3).
These results therefore indicate that pre-incubation of Aβ42 oligo-
mers with the two chaperones can suppress or decrease markedly the
oxidative stress, calcium dishomeostasis and toxicity caused by Aβ42.
3.5. Chaperones inhibited colocalisation of Aβ42 aggregates with PSD-95
preventing synaptic dysfunction
We next investigated by confocal microscopy whether chaperones
prevent the colocalisation of Aβ42 aggregates with PSD-95. The scat-
ter plots of ﬂuorescence signals over the highlighted areas are
shown in Fig. 5. A notable degree of colocalisation between Aβ42 olig-
omers and PSD-95 was observed in neurons treated for 1 h with Aβ42
oligomers, with respect to medium-administered neurons (Fig. 5).
Conversely, when we treated the neurons for 1 h with Aβ42 oligomers
pre-incubated with either Clu or α2M, the chaperones were found to
inhibit oligomer binding to the cell membrane thus preventing the
colocalisation with PSD-95 (Fig. 5, 18 dendrite sections were analyzed
for each samples). The fraction of Aβ42 puncta colocalising with
PSD-95 puncta was 1.2 ± 0.5% for medium-administered neurons,
59.9 ± 2.0% for neurons treated for 1 h with Aβ42 oligomers, 26.3 ±
1.8% for neurons treated for 1 h with Aβ42 oligomers plus Clu,
26.9 ± 1.9% for neurons treated for 1 h with Aβ42 oligomers plus
α2M. Similar data was achieved analyzing the colocalisation between
HypF-N oligomers and PSD-95 (Suppl. Fig. 4).The concentration of PSD-95 has been found to be signiﬁcantly
lower in the brain of AD patients with respect to normal brains [21].
Thus, we evaluated whether the prolonged treatment of rat hippo-
campal neurons with Aβ42 oligomers decrease PSD-95 levels. When
we treated the neurons with Aβ42 oligomers for 24 h, we observed
a lower degree of colocalisation with PSD-95 caused by a decreased
expression of PSD-95 (Fig. 5). In particular, in neurons treated for
24 h with Aβ42 oligomers the fraction of Aβ42 puncta colocalising
with PSD-95 puncta (29.3 ± 2.8%) was comparable to that observed
in neurons treated for 24 h with Aβ42 oligomers plus Clu or α2M
(24.6 ± 1.9% or 24.5 ± 1.7%, respectively). Similar data was achieved
analyzing the colocalisation between HypF-N oligomers and PSD-95
(Suppl. Fig. 4).
These results show that Aβ42 oligomers induce a decrease in
PSD-95 levels in a time-dependent manner, as previously reported
with Aβ40 [69], supporting a model of AD pathogenesis in which
soluble Aβ may be responsible for the cognitive impairment through
synaptic dysfunction [3]. In addition, the two extracellular chaper-
ones studied here are able to recover PSD-95 expression, avoiding
oligomer binding to the synapses, suggesting an important protective
effect of chaperones against oligomer-induced synaptic dysfunction.
4. Discussion
Clusterin (Clu) and α2-macroglobulin (α2M) are markedly in-
duced in neuropathological conditions such as AD, where they are
found associated with Aβ plaques, suggesting a physiological interac-
tion with Aβ [40–42,70–72]. Clu and α2M are also known to inhibit
amyloid ﬁbril formation in vitro [43–47]. In particular, it has been
Fig. 4. Suppression of Aβ42 oligomer toxicity by chaperones in rat primary neurons. Preformed Aβ42 oligomers were incubated in the absence or presence of the indicated chaper-
ones (Aβ42:chaperone molar ratios as described in the Materials and methods section) for the indicated time lengths (A) and for 1 h (B) and then added to the extracellular medium
of hippocampal (A) or cortical (B) neurons for 24 h. (C, D) Representative confocal scanning microscope images showing intracellular ROS levels in primary hippocampal (C) and
cortical (D) neurons from rat brains. Preformed Aβ42 oligomers were incubated in the absence or presence of the indicated chaperones (protein:chaperone molar ratio as described
in the Materials and methods section) for the indicated time lengths and then added to the extracellular medium of hippocampal (C) or cortical (D) neurons for 1 h. The green
ﬂuorescence arises from the CM-H2DCFDA probe that has reacted with ROS. The corresponding semi-quantitative values of the green ﬂuorescence signal are shown below the
confocal images. In all histograms, the values reported are means ± SD of three independent experiments carried out in triplicate. The single, double and triple asterisks indicate
signiﬁcant differences (p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001, respectively) versus neurons treated with Aβ42 oligomers.
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present during the aggregation and disaggregation of Aβ40, preventing
further growth and proliferation of aggregated species [73–77]. α2M
was also found to bind small oligomers, preventing their growth and/
or conversion into ﬁbrils [47]. Furthermore, Clu and α2M are known
to mediate the clearance of extracellular protein oligomers via endocy-
tosis [48–50]. It is unclear, however, if extracellular chaperones have an
ability to inhibit intrinsically the toxicity of Aβ misfolded oligomers,
with evidence that has being very sparse and often contradictory
so far. Indeed, some reports supported a toxicity-enhancing role for
extracellular chaperones [7,51,52], others claimed a protective action
[43,53,54] while one study demonstrated that the ratio of chaperone:
Aβ could determine whether the effect was protective or enhanced
toxicity [46].Important suggestions have been obtained using chaperones dis-
tinct from extracellular ones, or protein oligomers distinct from Aβ
oligomers. Indeed, it has been demonstrated that intracellular chap-
erones can prevent the toxicity of Aβ oligomers, sequestering and
converting them into large non toxic aggregates [78]. Our recent
data showed that different chaperones, including Clu and α2M, can
inhibit efﬁciently the toxicity of extracellularly added protein oligo-
mers formed by three different peptides and proteins in SH-SY5Y
neuroblastoma cells, provided the chaperones are incubated with
the preformed oligomers before the resulting mixtures are added to
the extracellular medium of the cells [54]. Such an inhibition is very
effective as it occurs even at low chaperone concentration [54].
Using HypF-N oligomers as a toxic species, the protective effect of
the chaperones was found to result from the ability of these proteins
Fig. 5. Representative confocal scanning microscope images showing Aβ42 oligomers colocalising with post synaptic densities in rat primary hippocampal neurons. Preformed Aβ42
oligomers were incubated in the absence or presence of the indicated chaperones (protein:chaperone molar ratios as described in the Materials and methods section) for 1 h and
then added to the extracellular medium of rat neurons for 1 h or 24 h, as indicated. Aβ42 aggregates and PSD-95 were monitored using mouse monoclonal 6E10 antibody and rabbit
polyclonal anti-PSD-95 antibody, respectively, and then with Alexa Fluor 488- and Alexa Fluor 594-conjugated antibody (red and green ﬂuorescence, respectively). The ﬁrst line
showed medium-administered neurons; the second line shows neurons treated for 1 h (left) or 24 h (right) with Aβ42 oligomers (12 μM monomer concentration); the third
and fourth lines shows neurons treated for 1 h (left) or 24 h (right) with Aβ42 oligomers plus Clu (third line) or α2M (fourth line). The cytoﬂuorograms of dendrite sections
show the red ﬂuorescence intensity (as pixel intensity, y axis) versus green ﬂuorescence intensity (x axis). For each sample, 18 cytoﬂuorograms were analyzed, each considering
one dendrite section. The histograms show the percentage of colocalisation on regions of interest (12–13 cells) using the ImageJ (NIH, Bethesda, MD, USA) and JACOP plugin
(rsb.info.nih.gov) softwares. Data are expressed as mean ± S.D. (n = 18 per group). The asterisks indicate signiﬁcant differences (p ≤ 0.05) with respect to neurons treated for
1 h with Aβ42 oligomers.
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larger species, in the absence of any signiﬁcant reorganisation of
their internal molecular structure [54].
The present work originated from this previous study and was
targeted to Aβ oligomers, extracellular chaperones and a context
closely related to AD, such as rat brains and cultured neurons. We
demonstrated that chaperones can inhibit in vivo the neurotoxicity
of high concentrations of pre-formed extracellular Aβ oligomers.
Such an ability adds to the well-established functions of extracellular
chaperones in inhibiting protein aggregation [43–47] and promoting
the clearance of protein aggregates [48–50]. In all our experiments,
the oligomers are formed before adding the chaperones, showing
that the protective action of the latter also includes neutralisation of
toxic oligomers after they have formed. Thus we can hypothesise
that chaperones neutralise Aβ42 oligomers through a binding mecha-
nism that promote the seeding of larger species, as previously dem-
onstrated with HypF-N oligomers [54]. The accumulation of Aβ
ﬁbrils as large plaques visible with optical microscopy and the associ-
ation of such plaques with extracellular chaperones is indeed sugges-
tive of this possibility.
Multiple lines of evidence indicate that there are two locales in
which Aβ oligomers play a role in AD pathogenesis and are implicated
in a synaptic failure, namely the intraneuronal and extracellular com-
partments [79–85]. A dynamic equilibrium seems to exist between
the pools of Aβ oligomers in the two locales; extracellular Aβ appears
to originate from intraneuronal Aβ [86]. Since Aβ is released extracel-
lularly from a membrane precursor protein, Aβ plaques accumulate
extracellularly and Aβ oligomers have an ability to impair cell viabilityfrom the extracellular space, we have chosen to focus on extracellularly
added oligomers rather than intracellular ones in all our experiments.
This is the ﬁrst report that molecular chaperones prevent Aβ42-
induced learning and memory impairments in hippocampal-injected
rat brains in vivo. Associated with this prevention is the reduction
of astroglial activation, astrogliosis, lipoperoxidation, and caspase-3
activation in these brains. In addition, chaperones were found to be
able to protect primary hippocampal and cortical neurons against
injuries caused by misfolded Aβ42 oligomers, by preventing Aβ42
binding to the dendrites. In future experiments it will be crucial to
determine whether chaperone-mediated neutralisation of Aβ42 oligo-
mers also act in transgenic mouse models.
Hence, these data elect extracellular chaperones as novel mole-
cules that are neuroprotective against amyloid-induced injury and
excellent candidates for the design and development of therapeutic
strategies for the prophylaxis and treatment of AD.
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